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Previous research has shown that involving patients in the decision-making process may improve their quality of life (QoL). Our
purposes were to assess: (1) whether early-stage breast cancer patients perceived that they had treatment choice with regard to
adjuvant chemotherapy, (2) what reasons patients provide for their perception of having had no choice of treatment and (3) whether
the perception of treatment choice is related to satisfaction with the assigned treatment, experienced chemotherapy burden and
current QoL. A total of 448 patients, treated between 1998 and 2003, filled in the questionnaire (response rate: 62%). Patients who
indicated that they had not perceived a choice regarding chemotherapy could tick off one or more reasons out of 10 reasons, or
provide their own reason(s). Quality of life was measured on a Visual Analogue Scale, by means of the EuroQol, and by means of the
Hospital Anxiety and Depression Scale. Of the 405 patients who had answered the question on treatment choice, 316 patients
(78%) had perceived no choice. The most frequently indicated reason for lack of choice was: ‘I follow the doctor’s advice.’ We found
no differences in the levels of satisfaction with assigned treatment and in how much of a burden they found chemotherapy between
patients who perceived a choice of treatment and those who did not. In general, the perception of choice seemed to have no impact
on QoL. However, we found an interaction effect, which indicated that the impact of perception of treatment choice on QoL was
dependent upon whether the patient had been treated with chemotherapy or not. Within the group of patients who had not been
treated with chemotherapy, the perception of having had a choice was related to lower current QoL. In cases when the decision to
be treated or not has potential consequences for the chance of survival, patients’ QoL may not be improved by the perception of
having had a choice of treatment.
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Over the years, health care providers have moved from a more
paternalistic approach to one that actively encourages patient
autonomy and shared decision-making. The involvement of
patients in making decisions about their own care may contribute
to medical care that is in harmony with patients’ wants and needs,
and may perhaps improve health outcomes. Patients who perceive
that they have decisional control in treatment decision-making
may regain a sense of control and mastery over their disease or
treatment (Morris and Royle, 1988; Hack et al, 1994; Street and
Voigt, 1997; Deadman et al, 2001), which may ultimately lead to a
higher quality of life (QoL) (Morris and Royle, 1988; Street and
Voigt, 1997; Deadman et al, 2001; Polsky et al, 2002; Mandelblatt
et al, 2003). For example, Polsky et al (2002) observed that patients
who believed they had had a choice of surgical treatment for breast
cancer reported higher QoL scores by means of a Visual Analogue
Scale at 5 months following surgery, than did patients who
perceived themselves to have had no control over the decision.
Similarly, Mandelblatt et al (2003) concluded that breast cancer
survivors, who felt that they had had no choice of treatment,
reported significantly less general satisfaction, more bodily pain
and lower mental health scores, 3–5 years after their primary
treatment.
Much research has been carried out into the impact of offering
choice of treatment in the domain of surgery for breast cancer,
because the majority of breast cancer patients have the option of
choosing between modified radical mastectomy and breast-
conserving therapy. Both treatments are equally effective, but
may be valued differently by patients. A number of studies showed
that breast cancer patients who had actually been offered a choice
of surgery had a better sense of psychological well being than
patients who had not been given a choice based on clinical
arguments, such as central position of the tumour, inadequate
tumour-to-breast ratio and multiple tumours (Morris and Royle,
1988; Al-Ghazal et al, 2000; Deadman et al, 2001). Other studies
observed similar differences in both physical and psychological
well being, between patients who felt that they had had a choice of
treatment and patients who believed they had had no choice of
treatment, irrespective of whether the choice had actually been
offered (Street and Voigt, 1997; King et al, 2000; Polsky et al, 2002;
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lMandelblatt et al, 2003). It seems that the subjective experience of
control over decisions is as important for patients’ QoL as actually
being offered a choice.
As well as improving the QoL, offering cancer patients the
opportunity to participate in making decisions regarding their
treatment may also increase satisfaction with treatment and care
received. Gattellari et al (2001) observed that patients who
perceived that they had shared the treatment decision with their
physician were significantly more satisfied with the consultation,
the amount of information and the emotional support received
from their physician, than patients who perceived the treatment
decision as having been made exclusively by themselves or their
physician. Benefits that have been observed in patients with
diseases other than cancer include: less stress, decreased levels of
symptom distress and concern about illness, increased functional
status, coping, control over illness, self-efficacy, understanding of
and commitment to the treatment plan and satisfaction with their
physician (Davison et al, 1995). Krupat et al (2000) observed that,
in the case of surgical patients, more perception of control was
related to more satisfaction with the care that patients had received
during their hospital stay.
In general, research has been carried out into patients’
perceptions of having had a choice of treatment in the case of
two equally effective treatments, such as mastectomy and breast-
conserving therapy. However, we believe that involving patients in
making decisions about treatment may also be important when
deciding between treatments that are not equally effective and
which may differ with regard to the values that patients attach to
the various consequences of each option. For example, decisions
about treatment with adjuvant chemotherapy imply a complex and
difficult trade-off between increased probability of survival and
deterioration in QoL, due to the side effects of the treatment. All
patients will experience the side effects, but only some patients will
actually benefit from this treatment. Patients’ preferences regard-
ing this trade-off have shown to vary widely (e.g., Jansen et al,
2001) and to differ from the preferences of doctors (e.g., Slevin
et al, 1990). Charles et al (1997) stress the importance of shared
decision-making in the case of adjuvant chemotherapy, because:
(1) several treatment options exist with different possible out-
comes and substantial uncertainty, (2) there is often no clear-cut
right or wrong answer and (3) the impact of the treatment on the
patient’s physical and psychological well being will vary. The
choice between two equally effective treatments, such as breast-
conserving therapy and mastectomy, may have other implications
for well being than the choice between a treatment that has the
potential to increase the chance of being cured at the costs of side
effects, or no treatment. As far as we know, in the case of adjuvant
chemotherapy, there are no studies that have examined the
perception of freedom in choice of treatment and its consequences
for QoL and satisfaction with treatment.
The purposes of this study were to assess: (1) whether early-
stage breast cancer patients perceived a choice of treatment with
regard to adjuvant chemotherapy, (2) what reasons patients
provide for having perceived no choice of treatment and (3)
whether perception of treatment choice is related to satisfaction
with the assigned treatment, the amount of chemotherapy burden
experienced and current QoL.
PATIENTS AND METHODS
Patients
Patients with early-stage breast cancer, who had (part of) their
primary treatment in the Leiden University Medical Center
between January 1998 and January 2003, received a letter of
invitation in which the study was explained. The exclusion criteria
were: metastasised disease and poor understanding of the Dutch
language. Patients could indicate on a reply sheet whether they
wanted to receive the questionnaire and could return this sheet in a
prepaid envelope. The questionnaire and a prepaid envelope were
sent to patients who responded positively to our request. Patients
who did not reply received one reminder.
Methods
Perceived treatment choice was measured by asking: ‘Do you feel
that you had a choice regarding treatment with adjuvant
chemotherapy? (yes/no).’ This question followed a question asking
whether the patient had been treated with adjuvant chemotherapy.
Patients whose perception was that they had had no treatment
choice were asked to tick off one or more reasons out of 10, or
provide their own reason(s) for this perception. The exact
formulation of the statements is given in Table 2. Note that only
four of the 10 reasons were exactly the same for patients who had
undergone chemotherapy and those who had not. This is because
some reasons do not apply to treatment with chemotherapy, for
example, ‘In my case chemotherapy is no use’, whereas others refer
only to treatment with chemotherapy. The 10 reasons were
formulated on the basis of prior qualitative research into the
determinants of patients’ preferences for adjuvant chemotherapy
and perceived freedom of treatment choice (Jansen et al, 2003).
Satisfaction with the assigned treatment was investigated by
asking, ‘Are you satisfied with the fact that you have (not) been
treated with chemotherapy?’. Patients could indicate their response
on a five-point rating scale, anchored by ‘very dissatisfied’ (1) and
‘very satisfied’ (5). The experienced chemotherapy burden was
explored by asking, ‘What is your experience of chemotherapy
treatment?’ and providing a five-point response scale, anchored
with ‘very difficult’ (1) and ‘very easy’ (5).
Current QoL was measured on (1) a Visual Analogue Scale,
ranging from 0 ‘death’ to 1 ‘perfect health,’ (2) by means of the
EuroQol utility scores (Dolan, 1997) and (3) by means of the
Hospital Anxiety and Depression Scale (HADS, Dutch version:
Spinhoven et al, 1997). The EuroQol utility score is derived by
weighing patients’ responses to five questions in various domains
of QoL (mobility, self-care, usual activities, pain/discomfort and
anxiety/depression). The resulting utility scores range from  1
‘worst QoL’ to 1 ‘best QoL’. The HADS was originally developed by
Zigmund and Snaith (1983) and has two subscales: anxiety and
depression. Each subscale contains seven questions that have four
response categories (0–3). The score for each subscale can range
from 0 to 21, with higher scores indicating more anxiety or
depression.
Analysis
Patient and clinical characteristics are shown by means of
descriptive methods. Differences in patient and clinical character-
istics between responders and nonresponders, and between
patients who perceived that they had a choice of treatment and
those who did not, were analysed by means of w
2 statistics (gender,
marital status, education, type of cancer and having experienced
chemotherapy) and independent samples t-test (age, time passed
since surgery until filling in questionnaire, time passed since
completion of chemotherapy until filling in questionnaire).
The impact of perceived treatment choice on satisfaction with
assigned treatment and on experienced chemotherapy burden was
analysed by means of univariate analysis of variance. The impact
of perceived treatment choice on the current QoL was analysed by
means of multivariate analysis of variance. Visual Analogue Scale
scores, EuroQol scores, HADS Depression and HADS Anxiety
scores were included simultaneously as dependent variables in this
analysis. Perception of treatment choice was included as a
between-group factor in all models. Patient and clinical character-
istics that turned out to be related to the perception of treatment
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analyses, either as a between-group factor (categorical variables),
or as a covariate (continuous variables).
RESULTS
Description of the patient group
Between February and April 2003, 719 patients were asked to
participate in the study. In all, 102 patients (14%) indicated that
they did not want to receive the questionnaire, five patients (1%)
were deceased, four patients were not eligible due to dementia (as
indicated by their family), six patients had moved, and 72 patients
(10%) did not respond at all. A total of 530 patients (74%)
indicated that they wanted to receive the questionnaire. In all, 448
questionnaires were returned (85% of 530; 62% of 719).
Characteristics of the 448 patients who returned the ques-
tionnaire and the 271 patients who did not fill in the questionnaire
are presented in Table 1. There were no differences between the
responders and nonresponders with regard to gender. However,
the nonresponders were slightly older and had experienced
adjuvant chemotherapy less frequently (both: Po0.01).
Perception of treatment choice
Of the 405 (90% of 448) patients who had answered the question
about perception of treatment choice, 316 patients (78%)
responded that they had perceived a lack of choice regarding
treatment with adjuvant chemotherapy. Characteristics of the two
patient groups (choice vs no choice) are presented in Table 2.
There were no differences in perception of treatment choice with
regard to gender (P¼0.63), marital status (P¼0.45), education
(P¼0.35), time passed since surgery until filling in the ques-
tionnaire (P¼0.14) and time passed since completion of
chemotherapy until filling in the questionnaire (P¼0.12). How-
ever, patients who had perceived a treatment choice had more
often been treated with adjuvant chemotherapy (Po0.01).
Furthermore, we observed a trend that patients who had perceived
treatment choice were slightly younger (P¼0.08). Thus, having
had adjuvant chemotherapy and age will be included in the
analyses of variance, because they are potential confounders of the
relationship between the perception of treatment choice and the
dependent variables.
An overview of the reasons for having the perception that there
was no choice of treatment is provided in Table 3. In the no-
chemotherapy group, the mean number of checked reasons was
2.33 (s.d.¼1.40; range 1–8) and in the chemotherapy group 3.89
(s.d.¼1.84; range 1–10). Both in the group of patients who had
been treated with adjuvant chemotherapy and in the group who
had not, the most frequently indicated reason for the perception of
lack of choice was: ‘I follow the doctor’s advice’ (chemotherapy
group: 86%, no-chemotherapy group: 57%). The second most
important reason was ‘I’ll do anything to be cured’ in the
chemotherapy group (75%) and ‘Chemotherapy is not necessary’
in the no-chemotherapy group (47%).
Relationship between perception of treatment choice,
satisfaction with assigned treatment and experienced
chemotherapy burden
In general (n¼407), the mean score for satisfaction with the
assigned treatment is 4.53 (70.76), which indicates that patients
were quite satisfied with their assigned treatment. The univariate
analysis showed a significant effect (Po0.01) for (not) having
experienced chemotherapy and for age (P¼0.01), but not for
perception of choice regarding treatment (P¼0.78), or for the
interaction between perception of treatment choice and having
experienced adjuvant chemotherapy (P¼0.56). The main effect for
age indicates that older patients were more satisfied with their
assigned treatment. Furthermore, patients who have undergone
chemotherapy (n¼170) are less satisfied with their assigned
treatment than patients who have not been treated with
chemotherapy (n¼226) (mean satisfaction scores after correction
for age: 4.33 vs 4.67). The perception of lack of treatment choice
has no impact on satisfaction with assigned treatment.
The mean score for experienced chemotherapy burden is 2.66
(71.06, n¼175), which means that, in general, patients had found
chemotherapy moderately difficult. The univariate analysis showed
no effect of either perceived treatment choice (P¼0.30) or age
(P¼0.11). Thus, experienced chemotherapy burden is not
influenced by the perception of no treatment choice.
Table 1 Patient and clinical characteristics of responders and non-
responders
Responders
(n¼448)
Nonresponders
(n¼271)
Age
Mean (s.d.) 60 (11) 63 (12)
Range 32–89 34–90
Gender
Female 445 (99%) 268 (99%)
Having experienced adjuvant
chemotherapy
Yes 171 (38%) 71 (26%)
Table 2 Patient and clinical characteristics of patients who perceived
treatment choice and those who did not (n¼405)
Choice
(n¼89)
No-choice
(n¼316)
Age
Mean (s.d.) 57 (11) 59 (10)
Range 36–89 32–85
Gender
Female 88 (99%) 314 (99%)
Marital status
Married/living (apart) together 65 (73%) 243 (77%)
Widowed/single/divorced 24 (27%) 73 (23%)
Education
o10 years 44 (50%) 182 (59%)
10–15 years 23 (26%) 66 (21%)
415 years 21 (24%) 62 (20%)
Time from surgery to filling in
questionnaire
Mean number of days (s.d.) 1118 (425) 1041 (437)
Range 337–1935 161–1923
Having experienced adjuvant
chemotherapy
Yes 56 (63%) 117 (37%)
Time from completion of
chemotherapy to filling in
questionnaire
(n¼56) (n¼117)
Mean number of days (s.d.) 1019 (422) 918 (354)
Range 332–2397 93–1853
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current QoL
The mean current QoL scores are presented in Table 4. The
multivariate analysis (overall results) showed a main effect for age
(Po0.01), but no main effects for perceived treatment choice or
having experienced adjuvant chemotherapy. There was a trend
towards an interaction effect between perceived treatment choice
and having experienced chemotherapy (P¼0.12). The main effect
for age indicates that, in general, older patients have a lower QoL.
The interaction effect means that the impact of perception of
treatment choice on current QoL is dependent upon experience
with chemotherapy.
The univariate tests showed a main effect for age for all QoL
instruments, except for HADS Anxiety. Furthermore, an interac-
tion effect between perception of treatment choice and (not)
having experienced chemotherapy was observed for all QoL
instruments (VAS, EuroQol, HADS Anxiety: Pp0.05, HADS
depression: P¼0.08).
The interaction effect of perceived choice and having experi-
enced chemotherapy pointed in the same direction for all QoL
instruments, indicating that, within the group of patients who had
perceived a treatment choice, not being treated with chemotherapy
was related to lower current QoL. In contrast, among the patients
who had not perceived a treatment choice, not being treated with
chemotherapy was related to higher current QoL scores.
To investigate this interaction effect in more detail, we repeated
the analysis using simple main effects (perceived choice within
chemo/no chemo group) and again including age as a covariate. In
the group of patients who had experienced chemotherapy, we
found no overall effect of perceived choice on QoL (P¼0.58).
Furthermore, none of the univariate effects for each of the QoL
instruments reached statistical significance. In the patient group
who had not been treated with chemotherapy, the overall effect of
perceived choice reached borderline significance (P¼0.07). The
univariate results showed significant effects of perceived choice for
the VAS (Po0.01), the EuroQol (P¼0.02) and for HADS
depression (P¼0.05). No effect was observed for HADS anxiety
(P¼0.21). Interestingly, patients who had perceived a treatment
choice experienced worse current QoL.
DISCUSSION
Perception of (no) treatment choice
Our first research goal was to explore whether breast cancer
patients perceived freedom of choice regarding treatment with
adjuvant chemotherapy. We found that 68% of patients, who had
undergone chemotherapy, and 86% of patients, who had not
experienced chemotherapy, reported that they had felt a lack of
choice in treatment decision-making. We believe that these
percentages are remarkably high, but we are not aware of previous
studies regarding the choice for adjuvant chemotherapy with
which we could compare our results.
In both treatment groups, the most frequently indicated reason
for having experienced a lack of treatment choice was, ‘I follow the
doctor’s advice.’ Previous research has shown that the influence of
specialist preferences on treatment choice may be considerable
(Stoevelaar et al, 1999), even to the extent that the strongest
predictor for the treatment decisions of patients with a life-
threatening illness is the physician’s treatment recommendation
Table 3 Reasons for the perception of lack of treatment choice
Reason n % Reason n %
Chemotherapy group (n¼116) No-chemotherapy group (n¼198)
I follow the doctor’s advice. 100 86% I follow the doctor’s advice. 112 57%
I’ll do anything to be cured. 87 75% Chemotherapy is not necessary. 93 47%
If it’s got to be done, than it’s got to be done. 60 52% I do not need chemotherapy in order to be cured. 89 45%
It’s to make sure. 54 47% If it’s not necessary, I would prefer not to have chemotherapy. 79 40%
Chemotherapy is necessary. 42 36% I let my doctor decide. 32 16%
Doing nothing is no choice. 33 28% Nobody is going to ask for chemotherapy. 20 10%
There is no alternative to chemotherapy. 33 28% In my case chemotherapy is no use. 12 6%
I let my doctor decide. 10 9% I haven’t had time to think about it. 8 4%
I haven’t had time to think about it. 10 9% I don’t ever want to have chemotherapy. 5 3%
Fate decided. 7 6% Fate decided. 3 2%
Other reasons 15 13% Other reasons 9 5%
Table 4 Mean current quality of life scores for Visual Analogue Scale,
EuroQol, HADS Anxiety and HADS Depression (n¼361)
Current quality of life Choice No choice Effects
Overall results: Perceived choice: P¼0.40
Chemotherapy: P¼0.54
Interaction: P¼0.12
Age: Po0.01
Univariate results:
Visual Analogue Scale
a
Chemo 0.77 0.75 Perceived choice: P¼0.28
(n¼54) (n¼105) Chemotherapy: P¼0.76
No chemo 0.69 0.77 Interaction: P¼0.01
(n¼28) (n¼174) Age: P¼0.02
EuroQol
a
Chemo 0.84 0.82 Perceived choice: P¼0.19
(n¼54) (n¼105) Chemotherapy: P¼0.57
No chemo 0.74 0.83 Interaction: P¼0.04
(n¼28) (n¼174) Age: P¼0.01
HADS anxiety
b
Chemo 4.37 4.87 Perceived choice: P¼0.35
(n¼54) (n¼105) Chemotherapy: P¼0.10
No chemo 5.93 4.53 Interaction: P¼0.05
(n¼28) (n¼174) Age: P¼0.18
HADS depression
b
Chemo 2.46 2.42 Perceived choice: P¼0.06
(n¼54) (n¼105) Chemotherapy: P¼0.18
No chemo 4.39 2.87 Interaction: P¼0.08
(n¼28) (n¼174) Age: Po0.01
aA higher score refers to better quality of life.
bA lower score refers to less anxiety
and depression.
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l(Siminoff and Fetting, 1991; Smitt and Heltzel, 1997; Nold et al,
2000). In the study by Nold et al (2000), women with breast cancer
reported that the surgeon was the most influential person in their
treatment decision for breast-conserving therapy and more
important than the fear of breast cancer or its recurrence.
Gurmankin et al (2002), in a study using hypothetical treatment
choices, observed that respondents are willing to follow the
doctor’s recommendation even if this goes against what is best
with regard to maximising health and against what they would
otherwise prefer. The results of our study suggest that the effect of
the specialist’s recommendation may be so strong that patients
perceive that they have no choice but to follow the specialist’s
advice.
The results also show that 75% of patients who had undergone
chemotherapy reported that their wish to do anything to be cured
was a reason for the perception of having had no choice of
treatment. In comparison, almost half of the patients in the no-
chemotherapy group thought that chemotherapy was unnecessary
and not needed to be cured, presumably because they believed that
their doctors would otherwise have recommended this treatment.
Thus, when stating that they have not perceived a treatment
choice, patients may mean other things besides being offered
choice of treatment by their doctor. These results are in agreement
with the observations by Charles et al (1998), who describe in a
qualitative study that many women were preoccupied with
avoiding the possibility of disease recurrence. For this reason,
these women believed that the only decision they could make was
to accept the treatment that was offered. Some women felt that they
had no choice but to undergo all relevant treatments available in
order to reassure themselves that they had done everything
possible to ‘fight’ their cancer. Furthermore, Charles et al reported
that breast cancer patients believed that the options of adjuvant
chemotherapy, or no adjuvant chemotherapy, were not of equal
value. As these options were frequently perceived as ‘doing
something’ vs ‘doing nothing’, patients felt that their illness
gave them no choice but to undergo treatment. In our study, 28%
of the patients who had undergone chemotherapy indicated that
this reason played a role in their perception of no choice of
treatment.
Impact of perception of treatment choice on satisfaction
with assigned treatment, experienced chemotherapy
burden and current QoL
Contrary to expectation, perception of lack of treatment choice
had no consequences for the level of satisfaction with assigned
treatment. Similarly, the perception of no treatment choice had no
consequences for experienced chemotherapy burden.
We found that, within the group of patients who had been
treated with adjuvant chemotherapy, perception of treatment
choice was not related to QoL. Furthermore, among the patients
who had not undergone adjuvant chemotherapy, the perception of
no treatment choice was related to higher QoL. These results are in
contradiction with the results observed in other studies. For
example, Mandelblatt et al (2003) observed that breast cancer
patients’ perceptions of no treatment choice were related to less
general satisfaction, more bodily pain and lower mental health
scores, 3–5 years post-treatment. Street and Voigt (1997) observed
that in early-stage breast cancer patients, perceived choice was
related to better QoL in the domain of physical well being (r¼0.27,
Po0.05) and functional well being (r¼0.28, Po0.05) during the
12 months following breast surgery. Furthermore, Polsky et al
(2002) concluded that perceived choice was related to better QoL
measured by means of the VAS (P¼0.03). The latter studies did
not observe differences in the perception of treatment choice and
its impact on QoL, between patients who had been treated by
means of a mastectomy and patients who had undergone breast-
conserving therapy. In the study by Mandelblatt et al (2003), the
potential impact on QoL of an interaction effect between treatment
undergone and perceived choice was not assessed.
However, the results of these studies were not straightforward.
Mandelblatt et al (2003) found no effect of the perception of lack of
treatment choice in the domains of: physical functioning, physical
role, general health, emotional role, vitality and satisfaction with
medical care. Street and Voigt (1997) did not observe a relation-
ship between the perception of no treatment choice and emotional
and social well being. Polsky et al (2002) did not find an impact of
the perception of no treatment choice on QoL beyond 5 months
after surgery when using the Visual Analogue Scale, and at none of
the measurement points (5 months, 1 year and 2 years following
surgery) when employing the Health Utilities Index (P¼0.10).
These results indicate that the effect of the perception of no
treatment choice on QoL may differ, depending on, for example,
the domain of QoL that is studied, the measurement instrument
that is used, the treatment decision under concern, and the time
passed between treatment decision and QoL assessment. In
view of these results and the results observed in our study, we
may conclude that the impact of the perception of no
treatment choice on QoL seems rather modest and deserves
further research.
If we adhere to the concepts of patient autonomy and shared
decision making, we may consider the perception of no treatment
choice as a negative outcome of treatment decision-making.
However, it may be naive to assume that all patients want, and
benefit from, active involvement in treatment decision-making
(Fallowfield, 1997). The nature of the risks and benefits involved in
different treatment options may influence the preferred involve-
ment in treatment decision-making. The choice for adjuvant
chemotherapy may have severe consequences because it may
influence overall survival. Furthermore, the side effects of
treatment could be considerable. In such situations, patients may
be more inclined to hand over the treatment decision to their
doctor. In such cases, patients’ QoL may not be improved by the
perception of having had a choice of treatment. In our study,
patients who reported that they had experienced a choice of
treatment and who had not been treated with chemotherapy
consistently showed the lowest current QoL scores. A potential
explanation for their low QoL scores may be that they feel very
responsible for their choice not to be treated with chemotherapy
and that they worry about the possibility of the disease recurring
and of having made the wrong treatment decision.
Limitations
As the nonresponders in our study were slightly older and had
been treated with chemotherapy less frequently, we may not be
able to generalise our results so that they refer to the whole
population of disease-free patients treated for early-stage breast
cancer within the past 5 years.
Another limitation of our study is that we do not know whether
patients had actually been offered a choice of treatment.
Furthermore, patients may have been provided with a choice,
but may not have experienced it as such because of difficulties with
the comprehension of information due to psychological distress
(e.g. anxiety, depression) or specific coping strategies (e.g. denial).
For example, Keating et al (2003) observed that, in one-third of
cases, patients and surgeons disagreed about whether both breast-
conserving therapy and mastectomy had been discussed. Patients
reported more often than surgeons that only one of both
treatments had been discussed.
However, we believe that the subjective experience of control
over decisions is as important, and perhaps even more important
for patients’ QoL as having actually being offered a choice. Our
interest lies in the impact of the subjective experience of having
had (no) treatment choice, because this is what the patient is left
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lwith once the treatment decision has been made. Independent of
whether or not treatment choice has actually been offered, the
subjective experience is what the patient remembers, and it
seems likely that it is this subjective experience that determines
the impact on QoL and satisfaction rather than having had
objective choice. In support of this hypothesis, a number of
studies have indeed shown that patients who had perceived a
choice of treatment had better psychological and physical
well being than patients who had not perceived a choice,
irrespective of whether the choice had actually been offered (Street
and Voigt, 1997; King et al, 2000; Polsky et al, 2002; Mandelblatt
et al, 2003).
CONCLUSION
Using a large sample of patients, treated for early-stage breast
cancer within the past 5 years, we have shown that, in general,
patients’ perceptions of no choice of adjuvant chemotherapy did
not have an impact on their satisfaction with assigned treatment,
their experienced chemotherapy burden and their current QoL.
However, patients’ perception of having had a treatment choice
may have negative consequences for current QoL scores in the case
when patients have not undergone chemotherapy. This may be due
to the fact that the decision about chemotherapy may have severe
consequences for both survival and QoL.
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